> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Review NDA on Opioid Withdrawal Drug
- URL: https://www.fdaweb.com/advisory-panel-to-review-nda-on-opioid-withdrawal-drug/
- Published: 2018-02-26T12:00:00.000Z
- Updated: 2026-09-14T23:25:32.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140849

*Federal Register* notice: FDA has announced a 3/27 Psychopharmacologic Drugs Advisory Committee meeting. Panel members are scheduled to discuss a U.S. WorldMeds NDA for lofexidine hydrochloride, indicated for mitigating symptoms associated with opioid withdrawal and facilitating completion of opioid discontinuation treatment. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-02-26/pdf/2018-03808.pdf?ref=fdaweb.com).